<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00251056</url>
  </required_header>
  <id_info>
    <org_study_id>DPM-CF-202</org_study_id>
    <nct_id>NCT00251056</nct_id>
  </id_info>
  <brief_title>Mannitol Dose Response Study in Cystic Fibrosis</brief_title>
  <official_title>A Phase IIa Randomised, Open Label, Dose Response Study to Determine the Optimum Dose of Dry Powder Mannitol Required to Generate Clinical Improvement In Patients With Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmaxis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pharmaxis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Many cystic fibrosis patients die of lung failure caused by repeated lung infections from
      thick, sticky mucus. Past studies have shown Bronchitol inhalation may help to facilitate the
      clearance of mucus by altering its rheology and replenishing the airway surface liquid layer
      in these patients, thereby enhancing the shift of stagnant mucus from the lungs. The study
      aim is to determine the optimal dose of mannitol to generate clinical improvement in patients
      with cystic fibrosis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FEV1</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>FVC</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>other measures of lung function</measure>
    <time_frame>various</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QOL</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sputum microbiology</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sputum clearance and cough</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>respiratory symptoms</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mannitol</intervention_name>
    <description>120mg BD</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mannitol</intervention_name>
    <description>40 mg BD</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mannitol</intervention_name>
    <description>240mg BD</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mannitol</intervention_name>
    <description>400mg BD</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of cystic fibrosis (sweat test/genotype)

          -  7 years or older

          -  FEV1 between 40% and 90% of predicted for height, age and gender.

          -  Able to perform acceptable-quality spirometry

          -  Clinically stable in the week up to study entry

          -  No additional antibiotics or additional oral steroids for a period of 14 days before
             study entry (routine antibiotics permitted)

        Exclusion Criteria

          -  Currently active asthma

          -  Subjects colonized with Burkholderia cepacia or MRSA

          -  Considered &quot;terminally ill&quot; or listed for transplantation

          -  Requiring home oxygen or assisted ventilation

          -  Concurrent illness that in the investigators opinion may contribute to an increased
             and unacceptable risk if the subject was enrolled in the study (e.g. significant
             varicies, portal hypertension, cor pulmonale)

          -  Significant episode of haemoptysis (&gt;60 mLs) in the previous 12 months

          -  Heart attack or stroke in last 3 months

          -  Known aortic or cerebral aneurysm

          -  Subjects who are breast feeding or pregnant.

          -  At risk females unwilling to use appropriate contraception to prevent pregnancy during
             the course of the study

          -  Subjects who have participated in another investigative drug study parallel to, or
             within 4 weeks of study entry.

          -  Known intolerance to mannitol or unable to take any form of bronchodilator
             medications.

          -  Uncontrolled hypertension, systolic BP &gt; 200 or diastolic BP&gt; than 100

          -  Concurrent use of beta blocker medication

          -  Concurrent use of hypertonic saline

        Canada:

          -  Concurrent use of other pharmacological mucolytic agents other than Pulmozyme

        Argentina:

          -  Concurrent use of other pharmacological mucolytic agents including Pulmozyme
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth Tullis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St Michaels Hospital, Toronto, Ontario, Canada</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Brett Charlton, MBBS PhD</last_name>
    <role>Study Director</role>
    <affiliation>Pharmaxis Ltd, Sydney, NSW, Australia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital de Niños Superiora Sor María Ludovica</name>
      <address>
        <city>La Plata</city>
        <state>Buenos Aires</state>
        <zip>B1904CSI</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Pediatrico</name>
      <address>
        <city>Resistencia</city>
        <state>Chaco</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Interzonal Especializado Materno Infantil (HIEMI)</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Niños</name>
      <address>
        <city>Caba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Pediatrico Dr Humberto J Notti</name>
      <address>
        <city>Mendoza</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BC Children's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H 3V4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Pauls Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Janeway Children's Health and Rehabilitation Center</name>
      <address>
        <city>St Johns</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1B 3V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth II Health Sciences Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 3A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences Corporation</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Michaels Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2005</study_first_submitted>
  <study_first_submitted_qc>November 7, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2005</study_first_posted>
  <last_update_submitted>August 27, 2008</last_update_submitted>
  <last_update_submitted_qc>August 27, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 29, 2008</last_update_posted>
  <responsible_party>
    <name_title>Brett Charlton</name_title>
    <organization>Pharmaxis Ltd</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mannitol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

